|
Quotes & Info
|
| CELG > SEC Filings for CELG > Form 8-K on 15-Jun-2012 | All Recent SEC Filings |
15-Jun-2012
Change in Directors or Principal Officers, Submission of Matters to a Vote of S
(e) At the annual meeting of stockholders (the "Annual Meeting") of Celgene Corporation (the "Company") held on June 13, 2012, the Company's stockholders approved an amendment (the "Amendment") to the Company's 2008 Stock Incentive Plan (the "Plan") to, among other things:
• Adopt an aggregate share reserve of 95,981,641 shares of our Common Stock. This number includes our current share reserve of 81,981,641 shares of our Common Stock and 14,000,000 additional new shares of our Common Stock.
• In connection with the increase in the aggregate share reserve, the "fungible" share limit, which limits the number of "full-value awards" (e.g., restricted stock and RSUs) that may be granted under the Plan by counting shares granted pursuant to such awards as multiple shares against the aggregate share reserve, will be changed from 1.6 shares for every share granted to 2.1 shares for every share granted.
• Extend the term of the Plan through April 18, 2022.
In addition to the foregoing, our stockholders reapproved the Section 162(m) performance goals under the Plan so that certain incentive awards granted under the Plan to executive officers of the Company may qualify as exempt performance-based compensation under Section 162(m) of the Internal Revenue Code.
The foregoing is a brief summary of the principal provisions of the amendments to the Plan and does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan, as amended by the Amendment, which Amendment is attached as Exhibit 10.1 and incorporated herein by reference.
(a) The annual meeting of stockholders of the Company was held on June 13, 2012.
(b) Stockholders voted on the matters set forth below:
Proposal 1. Election of Directors:
For Against Withheld Broker Non-Votes
Robert J. Hugin 307,901,783 N/A 8,956,466 50,102,750
Richard W. Barker, D.Phil. 314,191,067 N/A 2,667,182 50,102,750
Michael D. Casey 311,233,768 N/A 5,624,481 50,102,750
Carrie S. Cox 312,426,586 N/A 4,431,663 50,102,750
Rodman L. Drake 311,280,070 N/A 5,578,179 50,102,750
Michael A. Friedman, M.D. 315,053,581 N/A 1,804,668 50,102,750
Gilla Kaplan, Ph.D. 310,446,077 N/A 6,412,172 50,102,750
James J. Loughlin 309,089,445 N/A 7,768,804 50,102,750
Ernest Mario, Ph.D. 284,204,034 N/A 32,654,215 50,102,750
|
Proposal 2. Ratification of Appointment of KPMG LLP as the Company's Independent
Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2012:
For 356,109,800
Against 10,314,324
Abstain 536,875
Broker Non-Votes 50,102,750
|
For 247,036,030
Against 69,208,231
Abstain 613,988
Broker Non-Votes 50,102,750
|
Proposal 4. Advisory Vote on Executive Compensation:
For 302,226,159
Against 14,187149
Abstain 444,941
Broker Non-Votes 50,102,750
|
Proposal 5. Advisory Vote on Stockholder Proposal (described in more detail in the Proxy Statement):
For 189,500,550
Against 126,638,690
Abstain 719,009
Broker Non-Votes 50,102,750
(c) Not applicable.
|
(d) Not applicable.
(d) Exhibits
10.1 Amendment No. 2 to the Celgene Corporation 2008 Stock Incentive Plan
(Amended and Restated as of June 17, 2009)
|
|